Biocancell treatment gains FDA orphan drug status

Biocancell uses targeted therapy, focusing on the H19 gene, to treat cancer while preserving healthy surrounding tissue.

A pancreatic cancer fighting drug developed by Biocancell Therapeutics Ltd. (TASE:BICL) has been granted orphan drug status by the US Food and Drug Administration (FDA).

The FDA granted the status to the company's BC-819 treatment. Biocancell uses targeted therapy, focusing on the H19 gene, to treat cancer while preserving healthy surrounding tissue. The H19 gene is expressed at high levels in over 30 types of human cancer tissues, yet is at a nearly undetectable level in surrounding normal tissues.

The FDA designation means that if the drug reaches the market and is the first drug to be registered for this usage, it will receive 7 years of protection from competition. Orphan drug status is given by the FDA to treatments for diseases that affect 200,000 or fewer people in the US.

BC-819 is in a Phase I/IIa clinical trial against pancreatic cancer, and results are expected in several weeks. The drug is also in clinical trials against ovarian cancer and a Phase I/IIa trial against bladder cancer.

Published by Globes [online], Israel business news - www.globes-online.com - on August 15, 2010

© Copyright of Globes Publisher Itonut (1983) Ltd. 2010

5 Comments
View comments in rows
Update by email about comments talkback
POST
Comments
Your name
Please insert your name
Content
Hyperlink in a new window Hyperlink Right Left underline italic bold Bulleted List Ordered List Face1 Face2 Face3 Face4 Face5 Face6
Your comment

Thanks
You comment was recieved and soon will be published.
In posting comments, I agree to abide by the Terms of Use
Globes encourages lively and frank debate, but posts that the editors consider merely abusive or otherwise inappropriate will be removed. Report inappropriate content
Thank you for posting your comment, which will be reviewed for publication.
Loading Comments...load
Load more comments
Twitter Facebook Linkedin RSS Newsletters גלובס